Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1371-1376

  Fujita, Megumi ^a   Tohi, Makiko ^a   Sawada, Kyoko ^a   Yamamoto, Yasuhiro ^b   Nakamura, Tsutomu ^b   Yagami, Tatsurou ^b   Yamamori, Motohiro ^a   Okamura, Noboru ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

Mevalonate pathway; Ras; Renal cell carcinoma; Rho; Zoledronate

Indexed keywords

ALENDRONIC ACID; FARNESOL; FARNESYL DIPHOSPHATE; GERANYLGERANIOL; GERANYLGERANYL PYROPHOSPHATE; HOE 33342; MEVALONIC ACID; OXIDOREDUCTASE; PLACEBO; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; STAINING; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; MALE; METABOLIC NETWORKS AND PATHWAYS; MEVALONIC ACID; MICE; MICE, INBRED BALB C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863272461     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1683     Document Type: Article

References (28)

1. Amato RJ: Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16: 7-15, 2005.
2. Garcia JA and Rini BI: Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57: 112-125, 2007. (Pubitemid 46535711)
3. Gore ME and Larkin JMG: Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 104: 399-406, 2011.
4. Di Lorenzo G, Buonerba C, Biglietto M, et al: The therapy of kidney cancer with biomolecular drugs. Cancer Treat Rev 36: S16-S20, 2010.
5. Fujita M, Yagami T, Fujio M, et al: Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma. Cancer Lett 312: 219-227, 2011.
6. Elfiky AA, Aziz SA, Conrad PJ, et al: Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 11: 133, 2011.
7. Flaherty KT and Puzanov I: Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol 80: 638-646, 2010.
8. Russell RG, Xia Z, Dunford JE, et al: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 1117: 209-257, 2007. (Pubitemid 350191297)
9. Russell RG, Watts NB, Ebetino FH and Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733-759, 2008.
10. Dhillon S and Lyseng-Williamson KA: Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 68: 507-534, 2008. (Pubitemid 351342020)
11. Saad F and Eastham JA: Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 37: S38-S44, 2010.
12. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M and Ikeda Y: Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15: 719-727, 2003. (Pubitemid 36556076)
13. Tassone P, Tagliaferri P, Viscomi C, et al: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1981, 2003.
14. Sewing L, Steinberg F, Schmidt H and Göke R: The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13: 782-789, 2008.
15. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF and Scheper MA: Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 10: 2, 2011.
16. Merrell MA, Wakchoure S, Lehenkari PP, Harris KW and Selander KS: Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol 570: 27-37, 2007. (Pubitemid 47247687)
17. Rachner TD, Singh SK, Schoppet M, et al: Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287: 109-116, 2010.
18. Nogawa M, Yuasa T, Kimura S, et al: Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 15: 1-9, 2005. (Pubitemid 40470528)
19. Fritz G: Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 9: 626-638, 2009.
20. Pandha H, Birchall L, Meyer B, et al: Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol 176: 2255-2261, 2006. (Pubitemid 44633143)
21. Ullén A, Schwarz S, Lennartsson L, et al: Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 43: 98-103, 2009.
22. Skerjanec A, Berenson J, Hsu C, et al: The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 43: 154-162, 2003. (Pubitemid 36125942)
23. Shipman CM, Croucher PI, Russell RG, Helfrich MH and Rogers MJ: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294-5297, 1998. (Pubitemid 28551102)
24. Virtanen SS, Väänänen HK, Härkönen PL and Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62: 2708-2714, 2002. (Pubitemid 34462756)
25. Räikkönen J, Mönkkönen H, Auriola S, Harris KW and Selander KS: Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol 79: 777-783, 2010.
26. Miziorko HM: Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Arch Biochem Biophys 505: 131-143, 2011.
27. Zhuang L, Kim J, Adam RM, Solomon KR and Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115: 959-968, 2005. (Pubitemid 40489400)
28. Calleros L, Lasa M, Rodríguez-Alvarez FJ, Toro MJ and Chiloeches A: RhoA and p38 MAPK mediate apoptosis induced by cellular cholesterol depletion. Apoptosis 11: 1161-1173, 2006. (Pubitemid 44035965)